Synonyms: BLA 761046 | MBL-CDB1 | MDX-1388 | Zinplava®
bezlotoxumab is an approved drug (FDA (2016), EMA (2017), Japan (2017))
Compound class:
Antibody
Comment: Bezlotoxumab is a fully human IgG1 monoclonal antibody that binds to Clostridioides difficile toxin B [1]. It does not have inherent antibacterial activity but prevents binding of toxin B to colonic cells and reducing colonic cell inflammation. It is used to reduce the recurrence of C. difficile infection (CDI) in patients receiving antibacterial treatment for CDI.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes. FDA (2016) | EMA (2017) | Japan (2017) |
International Nonproprietary Names ![]() |
|
INN number | INN |
9608 | bezlotoxumab |
Synonyms ![]() |
BLA 761046 | MBL-CDB1 | MDX-1388 | Zinplava® |
Database Links ![]() |
|
Specialist databases | |
Antibiotic DB
![]() |
Bezlotoxumab, Zinplava |
IMGT/mAb-DB | 411 |
Other databases | |
CAS Registry No. | 1246264-45-8 (source: Scifinder) |
ChEMBL Ligand | CHEMBL2108670 |
DrugBank Ligand | DB13140 |
DrugCentral Ligand | 5186 |
GtoPdb PubChem SID | 496703304 |
Search PubMed clinical trials | bezlotoxumab |
Search PubMed titles | bezlotoxumab |
Search PubMed titles/abstracts | bezlotoxumab |
Wikipedia | Bezlotoxumab |